New agreement geared toward universal avian flu vaccine – CIDRAP
2025-04-22T20:10:00Z
The mRNA vaccine targets all major clades of the H5 avian flu subtype.
TG23/iStock
The University of Cambridge–based DioSynVax and Singapore’s ACM Biolabs have signed a deal to jointly develop a next-generation universal avian flu vaccine with the potential for mucosal delivery.
The mRNA vaccine targets all major clades of the H5 avian flu subtype and is scalable for rapid, global distribution, according to a press release from DioSynVax. Delivery via a nasal spray could help increase uptake of the vaccine.
mRNA vaccine will target H subtypes
DIOSynVax uses a platform of advanced artificial intelligence technology antigen design, while ACM Biolabs has a signature “ATP” delivery platform, designed to enable temperature stability and mucosal immunogenicity.
“Our joint technology platform combines powerful antigen design with state-of-the-art delivery systems with the potential for mucosal delivery, aiming to redefine a new generation of vaccines that are safer and stronger for today, smarter for tomorrow,” said Jonathan Heeney, DVM, ScD, PhD, chief scientific officer of DIOSynVax and professor of comparative biology at the University of Cambridge.
We believe this is a critical step toward equitable, rapid, and scalable flu vaccines.
“We believe this is a critical step toward equitable, rapid, and scalable flu vaccines, as well as vaccines to prevent the next pandemic.”
Auto-posted from news source
About The Author
